Highly motivated board-certified veterinary pathologist and PhD scientist with over 25 years experience in nonclinical drug development, toxicology and translational research who has worked on molecules from early research and target identification through product approval and post-marketing support. Passion for translational medicine, applied pathology and toxicology with a goal of understanding the on- and off-target safety profile and mechanisms of toxicity.  Experience with a variety of different types of therapeutics including, antibody-drug conjugates, small molecules, biologics, antibodies (monoclonal and bispecific), protein therapeutics, masked molecules, and gene therapy product candidates. Specific expertise in the nonclinical evaluation of antibody-drug conjugates including auristatin (MMAE and MMAF), maytansine, topoisomerase inhibitor, novel payloads and PBD conjugates; over 30 of which moved into clinical development and four of which are currently approved and marketed in oncology indications. Efficient and experienced in drafting module 2 documents as well as nonclinical sections of the IB and clinical protocols. Strategic forward thinking  approach to the design and implementation of nonclinical programs.